Description of Research Expertise

Epidemiology; Real-World Data; Discrete Choice Experiment; Clinical Trials

Selected Publications

Bewtra, Meenakshi; Schreiber, Stefan; Buisson, Anthony; Hur, Peter; Panattoni, Laura; Hauber, Brett; Gahlon, Grace; Coulter, Josh; Smith, Christina; Guo, Xiang; Land, Natalie; Wosik, Karolina; Cappelleri, Joseph; Maravic, Melissa Culhane; Walsh, Alissa : Comparing the benefit-risk tradeoffs advanced therapy naïve vs experienced patients are willing to accept when selecting advanced therapy for moderate-to-severe ulcerative colitis: A discrete choice experiment in the United States and Europe. Digestive Disease Week, San Diego CA May 2025.

Schreiber, Stefan; Buisson, Anthony; Bewtra, Meenakshi; Hur, Peter; Panattoni, Laura; Hauber, Brett; Land, Natalie; Coulter, Josh; Gahlon, Grace; Guo, Xiang; Smith, Christina C.; Cappelleri, Joseph C.; Wosik, Karolina; Maravic, Melissa Culhane; Walsh, Alissa: Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative Colitis: A discrete choice experiment. European Crohn’s and Colitis Organisation 2025; Berlin Germany February 2025.

Sehgal P, Lewis JD, Pickett-Blakely O, Nandi N, Bewtra M, Lichtenstein GR.: Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients. Clin Gastroenterol Hepatol Jan 2025.

Kastl AJ, Brenner EJ, Weaver KN, Zhang X, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine AM, Craig RG, Boccieri ME, Long MD, Kappelman MD.: Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis Oct 2024.

Motwani KK, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross RK; SPARC-IBD investigators.: Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis. Dig Dis Sci June 2024.

Motwani KK, Alizadeh M, Abutaleb A, Grossman J, Wellington J, Cross RK; SPARC-IBD investigators.: Correction to: Correlation Between Plasma and Fecal Biomarkers and Patient‑Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis. Dig Dis Sci June 2024.

Karakasheva TA; Martinez CM; Zhou Y; Rhoades JH; Soto GE; Hix OT; Nettleford SK; Roach DM; Laguerta AM; Thadi A; Aleynick D; Pickering OH; Borodyanskaya Y; Fulton M; Uzun Y; Li N; Bewtra M; Kelsen JR; Tan K; Minn AJ; Lengner CJ; Hamilton KE;: Crohn's Disease Epithelial Cells Exhibit Sustained Inflammatory Progenitor Cell States Digestive Disease Week, Washington DC May 2024 Notes: Oral presentation.

Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht A, Brensinger CM, Wu GD, Bittinger K; DINE-CD; SPARC IBD Investigators.: Surgery for Crohn's Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts. Cell Mol Gastroenterol Hepatol May 2024.

Sehgal P; Khanna T; Profka K; Pickett-Blakely O; Nandi N; Rashid F; Bewtra M; Lewis JD; Lichtenstein, GR; Aberra F.: Safety and Clinical Effectiveness of GLP1 Agonists in Inflammatory Bowel Disease Patients. Digestive Disease Week, Washington DC May 2024 Notes: Oral presentation.

Sehgal P; Khanna T; Profka K; Pickett-Blakely O; Nandi N; Rashid F; Bewtra M; Lewis JD; Lichtenstein, GR; Aberra F.: Impact of GLP1 agonists on inflammatory biomarkers in patients with IBD. Digestive Disease Week, Washington DC May 2024 Notes: Poster presentation.

back to top
Last updated: 03/13/2025
The Trustees of the University of Pennsylvania